Physician profile
Stacy Chimento
NPI 1962663443
$293,373.93
in general payments reported to CMS, 2019-2025
22 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $45K · 2021: $44K · 2022: $43K · 2023: $46K · 2024: $44K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Food and Beverage: $3,716 · Travel and Lodging: $1,736 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,550.00 |
| Food and Beverage | $3,715.82 |
| Travel and Lodging | $1,735.82 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $287,718.40 | 2019-2025 | Dysport |
| Abbvie INC. | $1,579.70 | 2019-2025 | Botox, Rinvoq, Skyrizi |
| Allergan, INC. | $1,087.06 | 2019-2022 | |
| Janssen Biotech, INC. | $433.98 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $417.10 | 2019-2025 | Dupixent |
| Pfizer INC. | $362.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $330.15 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $198.14 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Genzyme Corporation | $195.87 | 2021-2025 | |
| Lilly USA, LLC | $187.26 | 2019-2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.93 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Ucb, INC. | $156.61 | 2022-2025 | Cimzia, Bimzelx |
| Revance Therapeutics, INC. | $150.00 | 2024 | Daxxify |
| Merz North America, INC. | $103.64 | 2019 | |
| Celgene Corporation | $78.74 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $69.54 | 2025 | Nexplanon |
| Clozex Medical INC | $39.47 | 2022 | |
| Cipher Pharmaceuticals US LLC | $34.37 | 2025 | Natroba, Spinosad |
| Incyte Corporation | $28.42 | 2024 | Opzelura |
| Smith+Nephew, INC. | $24.15 | 2024 | Pico 14 |
| Biofrontera INC. | $14.41 | 2019 | |
| Mayne Pharma Commercial LLC | $4.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Chimento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.